Companhia Brasileira de Distribuição

CBD plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CBD stands at 218.1M. In comparison, DDS has a market cap of 6.8B. Regarding current trading prices, CBD is priced at $0.45, while DDS trades at $432.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CBD currently has a P/E ratio of -14.83, whereas DDS's P/E ratio is 11.98. In terms of profitability, CBD's ROE is -0.55%, compared to DDS's ROE of +0.28%. Regarding short-term risk, CBD is more volatile compared to DDS. This indicates potentially higher risk in terms of short-term price fluctuations for CBD.

CBD plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CBD stands at 218.1M. In comparison, JWN has a market cap of 4.1B. Regarding current trading prices, CBD is priced at $0.45, while JWN trades at $24.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CBD currently has a P/E ratio of -14.83, whereas JWN's P/E ratio is 14.17. In terms of profitability, CBD's ROE is -0.55%, compared to JWN's ROE of +0.30%. Regarding short-term risk, CBD is more volatile compared to JWN. This indicates potentially higher risk in terms of short-term price fluctuations for CBD.

CBD plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CBD stands at 218.1M. In comparison, M has a market cap of 3.4B. Regarding current trading prices, CBD is priced at $0.45, while M trades at $12.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CBD currently has a P/E ratio of -14.83, whereas M's P/E ratio is 6.33. In terms of profitability, CBD's ROE is -0.55%, compared to M's ROE of +0.13%. Regarding short-term risk, CBD is more volatile compared to M. This indicates potentially higher risk in terms of short-term price fluctuations for CBD.

CBD plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CBD stands at 218.1M. In comparison, KSS has a market cap of 1.1B. Regarding current trading prices, CBD is priced at $0.45, while KSS trades at $9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CBD currently has a P/E ratio of -14.83, whereas KSS's P/E ratio is 8.78. In terms of profitability, CBD's ROE is -0.55%, compared to KSS's ROE of +0.02%. Regarding short-term risk, CBD is less volatile compared to KSS. This indicates potentially lower risk in terms of short-term price fluctuations for CBD.

CBD plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CBD stands at 218.1M. In comparison, EXTO has a market cap of 585.7M. Regarding current trading prices, CBD is priced at $0.45, while EXTO trades at $3.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CBD currently has a P/E ratio of -14.83, whereas EXTO's P/E ratio is 90.25. In terms of profitability, CBD's ROE is -0.55%, compared to EXTO's ROE of +0.01%. Regarding short-term risk, CBD is less volatile compared to EXTO. This indicates potentially lower risk in terms of short-term price fluctuations for CBD.

CBD plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CBD stands at 218.1M. In comparison, DDT has a market cap of 409.2M. Regarding current trading prices, CBD is priced at $0.45, while DDT trades at $25.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CBD currently has a P/E ratio of -14.83, whereas DDT's P/E ratio is N/A. In terms of profitability, CBD's ROE is -0.55%, compared to DDT's ROE of +0.25%. Regarding short-term risk, CBD is more volatile compared to DDT. This indicates potentially higher risk in terms of short-term price fluctuations for CBD.